Publicaciones en colaboración con investigadores/as de Montreal Heart Institute (39)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis

    Cardiovascular Diabetology, Vol. 22, Núm. 1

  3. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

  4. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 6, pp. 570-582

2021

  1. Differences in platelet-rich plasma composition influence bone healing

    Journal of Clinical Periodontology, Vol. 48, Núm. 12, pp. 1613-1623

2019

  1. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study

    Journal of the American College of Cardiology, Vol. 73, Núm. 6, pp. 629-638

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2015

  1. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    PLoS ONE, Vol. 10, Núm. 4

2014

  1. Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: A prospective analysis of 22,272 patients

    PLoS ONE, Vol. 9, Núm. 7

  2. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: Findings from the international prospective CLARIFY registry

    International Journal of Cardiology, Vol. 176, Núm. 1, pp. 119-124

2013

  1. Relationship of Quality of Life With Procedural Success of Atrial Fibrillation (AF) Ablation and Postablation AF Burden: Substudy of the STAR AF Randomized Trial

    Canadian Journal of Cardiology, Vol. 29, Núm. 10, pp. 1211-1217

2012

  1. Incidence and significance of early recurrences associated with different ablation strategies for AF: A STAR-AF substudy

    Journal of Cardiovascular Electrophysiology, Vol. 23, Núm. 12, pp. 1295-1301

  2. Non-invasive imaging in acute chest pain syndromes

    European Heart Journal Cardiovascular Imaging, Vol. 13, Núm. 1, pp. 69-78

  3. Vorapaxar in the secondary prevention of atherothrombotic events

    New England Journal of Medicine, Vol. 366, Núm. 15, pp. 1404-1413

2011

  1. Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: A clinical-experimental correlation

    Heart Rhythm, Vol. 8, Núm. 9, pp. 1426-1433

2010

  1. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial

    The Lancet, Vol. 376, Núm. 9748, pp. 1233-1243

  2. Mechanisms by which adenosine restores conduction in dormant canine pulmonary veins

    Circulation, Vol. 121, Núm. 8, pp. 963-972

  3. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): A randomized, multicentre, international trial

    European Heart Journal, Vol. 31, Núm. 11, pp. 1344-1356

2009

  1. Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial

    JACC: Cardiovascular Interventions, Vol. 2, Núm. 11, pp. 1083-1091

  2. The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes

    American Heart Journal, Vol. 158, Núm. 2, pp. 201.e5